| abstract |
The present invention provides and describes solid state 17α-ethynyl-5α-androstane-3α, 17β-diol, such as amorphous and crystalline forms and certain polymorphic forms thereof. Anhydrous and solvates of 17α-ethynyl-5α-androstane-3α, 17β-diol include type III anhydrides and type I solvates. Furthermore, the present invention relates to solid and suspension formulations comprising the solid state forms of 17α-ethynyl-5α-androstane-3α, 17β-diol as described herein, and cancers such as prostate cancer or breast cancer in a subject or human patient or It relates to the use of the formulation for treating pre-cancer. The invention also relates to a method of making a liquid formulation from the solid state form of 17α-ethynyl-5α-androstane-3α, 17β-diol, and the use of such formulations in the treatment of the described medical conditions. |